Trinity Biotech Makes Leaps in CGM Technology
Dublin – Trinity Biotech plc (NASDAQ: TRIB), an innovator in biotechnology specializing in human diagnostics and diabetes management solutions that incorporate wearable biosensors, has recently released significant findings from its pre-pivotal trial. These findings emphasize marked advancements in the first-day performance of their next-generation continuous glucose monitoring (CGM) system.
Improving First-Day Accuracy for CGM Users
The results from the trial indicate an impressive 35% enhancement in the Mean Absolute Relative Difference (MARD) and over 50% improvement in the Mean Absolute Difference (MAD) when comparing Trinity Biotech’s new CGM sensor with its prior Waveform products. Addressing the first 24 hours of sensor wear—historically a challenging period with fluctuating accuracy—these improvements offer a reliable solution to a common pain point for users. Inconsistent glucose readings during this critical time can contribute to frustration and safety risks, making this advancement crucial for diabetes management.
Overview of the Pre-Pivotal Trial
The latest pre-pivotal trial conducted by Trinity Biotech showcased the participation of 30 diabetic individuals, primarily with Type 1 diabetes, over a span of 15 days, during which they utilized several sensors. This trial particularly focused on how enhancements made by the R&D team to the technology acquired from Waveform Technologies, Inc. have influenced sensor performance.
Impressive Results Beyond First-Day Accuracy
In addition to remarkable first-day accuracy improvements, the trial yielded several other favorable results:
- Superior Signal Quality: Enhanced signal clarity compared to previous iterations of Waveform CGM sensors.
- Consistent Reliability Post-Insertion: After placement, the sensors demonstrated a more stable performance, thus reducing variability and enhancing user experience.
- Notable Accuracy Boost: A 25-30% improvement in the key accuracy metric MARD over earlier Waveform CGM models.
- Precision in Low-Glucose Readings: Accuracy for low glucose measurements has now aligned with industry standards, a vital advancement for managing hypoglycemia.
Transforming Accessibility and Performance in CGMs
Trinity Biotech's newly designed ergonomic modular CGM system focuses on affordability, accuracy, and sustainability. By creating reusable and rechargeable components, the system aims to lower costs for users and lessen environmental impact. This paradigm shift not only promises to provide continuous glucose monitoring to a broader audience but also caters to individuals who may have found prior solutions economically unfeasible.
Looking Ahead: Steps Towards Commercialization
With a renewed confidence in offering a calibration-free high-performance CGM system that adheres to FDA’s iCGM standards, Trinity Biotech is steering towards regulatory submissions in Europe by 2025, with a U.S. FDA filing expected in 2026. The company is keen on commercialization that targets both diabetes patients and health-conscious individuals. Building on the successful outcomes of this recent trial, plans are already in motion for additional pre-pivotal clinical trials in the coming months to explore further device enhancements.
Stay Informed About CGM Innovations
For the latest developments regarding Trinity Biotech's advancements in continuous glucose monitoring, you can stay updated through their official channels.
About Trinity Biotech
Trinity Biotech is a dynamic biotechnology company specializing in diabetes management solutions and human diagnostics. This includes a range of diagnostic systems for point-of-care and clinical laboratory segments. Following their acquisition of the biosensor assets from Waveform Technologies Inc., they are venturing into wearable biosensors, initiating with their continuous glucose monitoring product. Their solutions are pivotal in detecting infectious diseases and measuring key health markers, like Hemoglobin A1c levels. With a global reach, Trinity Biotech operates directly in the United States and through a network of distributors and partners across more than 75 countries.
Frequently Asked Questions
What improvements were observed in Trinity Biotech's CGM trials?
The trials showed a 35% enhancement in first-day accuracy and a 50% improvement in Mean Absolute Difference (MAD).
How many participants took part in the recent CGM trial?
The trial involved 30 diabetic individuals, mostly with Type 1 diabetes, each wearing multiple sensors over a 15-day period.
What benefits do the new CGM sensors provide?
They offer superior signal quality, enhanced reliability post-insertion, and precision in low-glucose readings aligned with industry standards.
When does Trinity Biotech plan to submit regulatory filings?
They are targeting regulatory submissions in Europe for 2025 and a U.S. FDA filing in 2026.
What is the focus of Trinity Biotech's future developments?
Their focus includes advancing technology for diabetes management solutions and enhancing existing device capabilities through further trials.
